Maker Yielding Patent in Africa for AIDS Drug
March 15, 2001
Bristol-Myers Squibb has decided to give other companies the right to produce generic formulations of its stavudine AIDS drug for the African market. The company is also bringing the price of stavudine and didanosine to a combined $1 dollar per day for African nations. Executive vice president John L. McGoldrick asserts that his company is more interested in helping manage the continent's devastating epidemic than in making profits. ACT-UP Philadelphia's Kate Krauss states that the Bristol-Myers Squibb initiative is unprecedented in that the company admits that generic drugs are integral in saving lives, but activists remain disappointed that the company has not removed itself from the lawsuit against the South African government.Adapted from:
Other CDC News for March 15, 2001
New York Times (www.nytimes.com)
03/15/01; P. A1; Petersen, Melody; McNeil Jr., Donald G.
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.